SCHEMBL1120301

SCHEMBL1120301

CC(C)(C)[Si](C)(C)OC(=O)C(F)(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21054373 0.82
SCHEMBL27051439 0.80 ELANE (0.32)
SCHEMBL27553183 0.79
SCHEMBL1050079 0.77
SCHEMBL423208 0.77
SCHEMBL4265048 0.77
SCHEMBL28601036 0.75
SCHEMBL31477856 0.75
SCHEMBL28706826 0.74
SCHEMBL1061431 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025052986-A1 SUBSTRATE TREATING METHOD AND SUBSTRATE MANUFACTURING METHOD セントラル硝子株式会社 2025-03-13 WO disclosed
EP-4261830-A1 NOVEL PEPTIDOMIMETIC COMPOUND AND DESIGN Oita University Institute of Advanced Medicine, Inc. (JP) 2023-10-18 EP disclosed
WO-2022124341-A1 NOVEL PEPTIDOMIMETIC COMPOUND AND DESIGN 株式会社大分大学先端医学研究所 2022-06-16 WO disclosed
US-20220123363-A1 ELECTROLYTIC SOLUTION AND ELECTROCHEMICAL DEVICE USING THE SAME NINGDE AMPEREX TECHNOLOGY LIMITED (CN) 2022-04-21 US disclosed
EP-2280989-B1 CYCLOSPORIN ANALOGS AND THEIR USE IN THE TREATMENT OF HCV INFECTIONS SCYNEXIS INC (US) 2016-02-10 EP disclosed
US-9090671-B2 Macrocyclic peptides SCYNEXIS, INC. (US) 2015-07-28 US disclosed
EP-2509615-A1 NOVEL CYCLIC PEPTIDES Scynexis, Inc. (US) 2012-10-17 EP disclosed
WO-2011070364-A1 NOVEL CYCLIC PEPTIDES SCYNEXIS, INC. (US) 2011-06-16 WO disclosed
US-20110144005-A1 NOVEL CYCLIC PEPTIDES SCYNEXIS, INC. 2011-06-16 US disclosed
EP-2280989-A2 CYCLOSPORIN ANALOGS AND THEIR USE IN THE TREATMENT OF HCV INFECTIONS Scynexis, Inc. (US) 2011-02-09 EP disclosed
US-5681951-A REACTING PENICILLIN DERIVATIVE HAVING SULFINYL OR SULFONYL GROUP IN 2 POSITION WITH SUBSTITUTED MERCAPTAN IN PRESENCE OF SALT OF GROUP IIA OR IIIA ELEMENT SANKYO COMPANY, LIMITED (JP) 1997-10-28 US disclosed
US-5637742-A Vitamin D compound, method of preparing this compound and intermediate therefor DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 1997-06-10 US disclosed
US-5614624-A THIO SUBSTITUTED, ANTIBIOTICS, CHEMICAL INTERMEDIATES SANKYO COMPANY, LIMITED (JP) 1997-03-25 US disclosed
EP-0521550-B1 Vitamin D compound, method of preparing this compound and intermediate therefor DUPHAR INT RES (NL) 1996-09-18 EP disclosed
US-5541317-A PENICILLIN DERIVATIVES, CYCLIZATION OF ESTERS OR THIOESTERS SANKYO COMPANY, LIMITED (JP) 1996-07-30 US disclosed
US-5403940-A Vitamin D compound, method of preparing this compound and intermediate thereof DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 1995-04-04 US disclosed
US-5395953-A Method of preparing hydrindane compounds and hydrindane-related compounds DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 1995-03-07 US disclosed
EP-0594229-A1 Method of preparing hydrindane compounds and hydrindane-related compounds DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1994-04-27 EP disclosed
EP-0521550-A2 Vitamin D compound, method of preparing this compound and intermediate therefor DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1993-01-07 EP disclosed
EP-0516486-A2 Azetidinone derivatives useful in the preparation of carbapenem antibiotics Sankyo Company Limited (JP) 1992-12-02 EP disclosed